An observational study in Sexually Transmitted Diseases, sponsored by GlaxoSmithKline. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by GlaxoSmithKline · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 11th largest by planned enrollment of the 30 observational ones that give a count, is one of 12 that started in 2026, is one of 30 observational ones, reaches primary completion later than 41 of the 41 other live ones, and was the 282nd registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:
Westat · Sites in United States
Ages 13–24 · Men only · Healthy volunteers
Emory University · Sites in United States
Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 13–21 · Men only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 15 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 15 · Phase 4 12
First in 1993; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 614 is close to the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.
Median enrollment 400 across the 251 interventional studies, 280 across the 30 observational. Of the 227 that completed or were terminated, 76 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 283 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
GlaxoSmithKline has 4 studies filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
16 of the studies in Sexually Transmitted Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06183502Emory UniversityHIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men | 2026-11 |
| NCT07089836American Laboratory Products CompanyThis Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests. | 2026-12 |
| NCT07281599QurasenseEvaluation of the Q-Pad hrHPV Test System for Identifying Precancer | 2026-12-31 |
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT04372875Children's National Research InstituteHealth Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.
Pregnant participants with uncomplicated urinary tract infection who are exposed to gepotidacin or standard-of-care antibiotics during the relevant exposure window.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Both cohorts:
Exposed cohort:
Comparator cohort:
Exclusion Criteria:
For Both cohorts:
Exposed cohort:
Comparator cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to gepotidacin during the relevant exposure window
Other: None (Observational study)
Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to standard-of-care antibiotics during the relevant exposure window
Other: None (Observational study)
Not Applicable since Observational Study
Also known as: Observational Study
Not Applicable since Observational Study
Also known as: Observational Study
Number of infants with major congenital malformations (MCMs)
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.
Time frame: At pregnancy outcome, with follow-up through 12 months after delivery
Number of infants with small-for-gestational-age births (SGA)
A newborn infant whose birth weight is less than (\<) 10th percentile for sex and gestational age using standard growth charts for full- and preterm live-born infants.
Time frame: At live birth
Number of infants with minor congenital malformations
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.
Time frame: At live Birth, with follow-up up through 12 months of age
Number of participants (pregnant women) with pregnancy termination
A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or because of fetal abnormalities.
Time frame: From date of conception (DOC) to <20 gestational weeks
Number of participants (pregnant women) with spontaneous abortions (SAB)
An involuntary fetal loss or the expulsion of the products of conception occurring at less than (\<) 20 gestational weeks.
Time frame: From date of conception (DOC) to <20 gestational weeks
Number of participants (pregnant women) with stillbirths
Stillbirth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at greater than or equal to (\>=) 20 weeks of gestation, or, if gestational age is unknown, a fetus weighing \>=350 grams.
Time frame: From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with preeclampsia
Preeclampsia is disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria, or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following: Thrombocytopenia: platelet count \<100,000/milliliter (mL). Renal insufficiency: serum creatinine concentrations \>1.1 milligram per deciliter (mg/dL) or a doubling of the serum creatinine concentration in the absence of other renal disease. Impaired liver function: elevated blood concentrations of liver transaminases to twice the normal concentration. Pulmonary edema. New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms
Time frame: From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with eclampsia
New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.
Time frame: From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with gestational hypertension
Blood pressure greater than 140 millimeter of mercury (mmHg) systolic or 90 mmHg diastolic on 2 separate occasions at least 4 hours apart after 20 weeks of pregnancy when previous blood pressure was normal.
Time frame: From 20 weeks' gestation to pregnancy outcome
Number of participants (pregnant women) with gestational diabetes
Any degree of glucose intolerance with onset or first recognition during pregnancy.
Time frame: At pregnancy outcome
Number of participants (pregnant women) with preterm births
Preterm birth is defined as a live birth occurring at \<37 gestational weeks.
Time frame: At live birth, if occurring before 37 gestational weeks
Number of infants with postnatal growth deficiency
Weight, length, or head circumference in \<10th percentile for sex and chronological age using standard growth charts
Time frame: At 4 and 12 months of infant age
Number of infants with developmental delay
Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention.
Time frame: At 4 and 12 months of infant age
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2032, 70 months after the start.
Of 48 observational studies under Sexually Transmitted Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 70 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →